![System.Func`1[System.String]](/siteassets/images/z-mckesson-logosicons/specialty-practice-solutions.png)
For oncology and other specialty oral and self-injectable medications, our end-to-end process and tools allow your practice to effectively purchase, dispense, and bill self-administered therapies for a seamless treatment experience.
Establishing a new revenue stream doesn’t have to be disruptive to your practice or patients. The experts at McKesson can help you implement a new medically integrated dispensary (MID) or optimize your existing program to support the high-quality, efficient delivery of self-administered therapies directly to your patients. In fact, we help over 1,800 dispensing clinicians fill more than 984,000 prescriptions per year.
From sourcing medication and supplies through our GPO to technology solutions to network access through our Pharmacy Services Administrative Organization (PSAO), Health Mart Atlas, our end-to-end process and tools allow your practice to effectively purchase, dispense, and bill self-administered therapies for a seamless treatment experience. Discover the confidence that comes from having insightful advisors who collaborate with you to grow your business.
The role of orals and self-injectable medications in community oncology continues to grow. The experts at McKesson can help your practice understand if a medically integrated pharmacy or dispensary is right for you, plus provide tools and best practices to enhance your business. From assessment to implementation to optimization, discover how we’re all-in to understand and support your practice needs.
ScriptPASTM, Patient Access Support, is a program designed to increase script capture for the MID by performing a benefit investigation to assess if the practice’s MID pharmacy can fill the prescription. It assists practices with reducing barriers to access and provides front-end support for pharmacy prescription processing.
It’s flexible, too. ScriptPAS is an à la carte, fee-for-service offering, which means less time on administrative tasks and more time for patients. Supporting either new or existing medically integrated pharmacies and dispensaries, ScriptPAS blends seamlessly with your current prescription processes to reduce operational challenges and save time. Contact us to learn how ScriptPAS can help your practice.
Discover how Rocky Mountain Cancer Centers quickly moves prescriptions through prior authorization with ScriptPAS. (PDF, 600 KB)
Our pharmacy advisors can help take your dispensing to the next level. With years of pharmacy management and operations experience, they analyze, observe, and recommend clinically sound, evidence-based action plans to increase profit, decrease cost and improve efficiencies.
Medically integrated dispensing is quickly becoming fundamental to community oncology, despite the increase of Pharmacy Benefit Manager (PBM)-owned central fill pharmacies. To support filling scripts beyond first fill, McKesson has joined IntegratedRx® - Oncology, a clinically integrated program developed by Prime Therapeutics that streamlines the treatment pathway and connects the patient to the physician for continuous care. Discover how IntegratedRx - Oncology helps your practice improve speed to therapy, drives adherence and provides access to patients.
*Over 95% of cases completed in 5 or fewer days. Individual results may vary based on case complexity and our receipt of the necessary prescription and patient information.
Alliance Cancer Specialists implemented a medically integrated dispensary program at 2 of their 11 locations. After learning that the revenue generated from these locations did not benefit the other nine, they worked with McKesson to better understand state dispensing regulations, expanded their operations and doubled their prescription volume.
By leveraging ScriptPAS to process challenging prescriptions with complex prior authorization requirements, Rocky Mountain Cancer Centers has not only decreased prescription leakage but has also recaptured over $27K in additional profit and experienced a return on investment (ROI) of 1500%.
Community specialty practices gain controlled access to specialty drugs through our direct-to-provider wholesale distribution.
This biosimilars master class was developed with Dr. Robert Rifkin and a team of expert clinical specialists to understand biosimilar drugs from the FDA view.
Specialty care requires a special approach—one that’s done your way. Let’s connect, and explore how McKesson can optimize your specialty practice.